Navigation Links
Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Date:8/27/2007

Quark's Novel siRNA Structures Exhibit Stability and Activity in vitro

FREMONT, Calif., Aug. 27 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that the Company has filed a patent application covering a number of novel chemical modifications that confer to the siRNA molecule stability and excellent penetration into the human cells tested.

"With the submission of this patent application, we believe we have provided significant additional protection for our pipeline program," said Daniel Zurr, President and CEO of Quark. "Filing of this patent application marks a significant step in our efforts to solidify our position as a leader in the RNAi therapeutics space, as the new structures allow us more flexibility with regard to intellectual property. We believe our future siRNA therapeutics will be less dependent on in-licensed rights to RNAi technology. This patent application adds the element of structural design to our expertise in identifying clinically attractive drug targets using a proprietary discovery platform and local or systemic delivery."

The patent application relates to new classes of chemically modified siRNA structures that have been tested in cell culture and have demonstrated enhanced stability, silencing activity, and cell penetration. Several new molecules are currently in preclinical testing. This research is part of Quark's program to develop novel synthetic siRNA patterns with drug-like properties as well as improved targeted delivery systems.

Currently, Quark owns or controls 30 issued U.S. and European patents, and has 200 patent applications pending, covering its technology, drug candidates, target genes and pipeline products.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drug candidates that
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...Nov.24/PRNewswire/--ZargisMedicalCorp.,asubsidiary...nsCorporateResearch(NYSE: SI ),todayannouncedthati...,2009episodeofCBS, TheEarlyShow duringasegmentinwh...reviewedfivewinningproductsfromthepublication,s200...idely-viewedtelevisionmorningnewstalkshowbroadcast...
(Date:11/24/2009).../PRNewswire/--AmbitBiosciencesCorporationannounced...gAC220,anovelsecondgenerationFLT3inhibitor,inAMLat...H)tobeheldinNewOrleans,LA,December5-8,2009.Anoralp...alPhaseImonotherapysafetystudyinadultswithacutemye...lbepresentedevaluatingtheeffectofAC220monotherapya...
(Date:11/24/2009)...Nov.24/PRNewswire-FirstCall/--EchoTherapeutics,Inc...le-freeSymphony(TM)tCGMSystemasanon-invasive,wirel...stemanditsPrelude(TM)SkinPrepSystemfortransdermald...,ChairmanandChiefExecutiveOfficer,willpresentatthe...ence,sponsoredbytheNewYorkSocietyofSecuritiesAnaly...
Breaking Medicine Technology:Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 3Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 1Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 2Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 3Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 4Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 2InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 1InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 2
...rius Therapeutics, Inc. announced,today that it in..., an,antibacterial drug candidate intended for tre...erial infections, including those caused by MRSA,a...subject single and,multiple ascending dose trial w... of the oral dosage form of the drug and will comp...
...Jan. 7 AtriCure, Inc.,(Nasdaq: ATRC ), a medical...blation products, today announced that results rep...sive products, which physicians have adopted to,tr...e Annals of Thoracic,Surgery by Dr. James H. Wudel... the Nebraska Heart Hospital, Lincoln, Nebraska., ...
Other Medicine Technology:Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701 2Positive Results Published Using AtriCure Minimally Invasive Products 2Positive Results Published Using AtriCure Minimally Invasive Products 3Positive Results Published Using AtriCure Minimally Invasive Products 4
(Date:11/25/2009)... Adam DreamHealer’s Global Inte...tentions changes the physiology of someone at a di...ntions at a time unknown to a volunteer who was mo...ed by world experts in the USA and Canada. , ... 25, 2009 -- Adam DreamHealer’s Global Int...
(Date:11/25/2009)... New minimally-invasive procedures th...and decrease the risk of sinusitis, or sinus infec...ns of the Atlanta Snoring Institute. Techniques s...ted sinuses without having to remove any bone or t...tages of these breakthroughs in treating sinus sym...
(Date:11/24/2009)...physicians with a computerized order entry/decisio...regarding imaging appropriateness at the time of o...maging utilization, according to an article in the...llege of Radiology , (JACR, www.jacr.org ). , "...sive, and often more costly, diagnostic techniques...
(Date:11/24/2009)...ADELPHIA,Nov.24/PRNewswire-USNewswire/--OnFriday,N...odriguezreceivedafatalblowtotheheadduringatitlebou...afteralleffortstosavehislifewereconducted,hewasdec...am--thenonprofitorganprocurementorganization(OPO)s...ware--wascontactedbythehospitalaspartofstandardcli...
(Date:11/24/2009)...ERSPRING,Md.,Nov.24/PRNewswire-USNewswire/--Partie...dareallpartoftheholidaycheer.Butthemerrimentcancha... http://www.newscom.com/cgi-bin/prnh/20090824/FDAL...miting,diarrhea,andflu-likesymptoms,whichcanstarta...sareconsumed. ,, "Thegoodnewsisthatpracticingfo...
Breaking Medicine News(10 mins):Health News:Intriguing Scientific Results from World's Largest Intention Healing Project: DreamHealer 2Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 2Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 3Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 4Health News:Computerized order entry/decision support systems: Effective solution to managing imaging utilization 2Health News:Paying Tribute to Boxer Francisco 'Paco' Rodriguez 2Health News:FDA Consumer Health Information: Food Safety Tips for Healthy Holidays 2
... High Level of Volunteer ... Professionals. , Chicago...sident of the Association of periOperative Registe... Ships, the operator of the world’s largest ...
...ifferences associated with behavioral traits, susc...Y, March 24 (HealthDay News) -- U.S. researchers h... in the human genome of blacks and 1,972 in whites...human diversity and can also be associated with be...
... The National Institutes of Health (NIH) will co...d Reinvestment Act (ARRA) to support autism resear... by a federal advisory committee. The Request for ...sents a surge in NIH,s commitment to finding the c...
... Fraser: Minnesota,s leading provider of autism se...ide information about autism. , , MINNEAPOLIS, M...al disability in the U.S., affecting 1 in 150 chil... combined. It is one of our community,s most urgen...
... School-Based Dental Prog... St. Cloud, Minn. (Vocus) March 24,...ewide preventive dental program to St. Cloud Area ...Across Minnesota provides children ages three to 1...
... Plus: Doctors, Hospital Picks by Specialty and Ti...me for Medical Care , WASHINGTON, March 24 AAR...mericans and the world,s largest-circulation magaz...(available at www.aarp.org/health ) was compiled ...
Other Medicine News:Health News:AORN and Mercy Ships Collaborate to Increase Patient Care Aboard Hospital Ships 2Health News:AORN and Mercy Ships Collaborate to Increase Patient Care Aboard Hospital Ships 3Health News:Study IDs Variations in Black, White Genomes 2Health News:NIH will use $60 million in Recovery Act funds to support strategic autism research 2Health News:NIH will use $60 million in Recovery Act funds to support strategic autism research 3Health News:April is Autism Awareness Month 2Health News:April is Autism Awareness Month 3Health News:Smiles Across Minnesota Expands Program to St. Cloud 2Health News:Smiles Across Minnesota Expands Program to St. Cloud 3Health News:Smiles Across Minnesota Expands Program to St. Cloud 4Health News:AARP The Magazine Unveils Top-Ranked Hospitals Across The Country 2Health News:AARP The Magazine Unveils Top-Ranked Hospitals Across The Country 3Health News:AARP The Magazine Unveils Top-Ranked Hospitals Across The Country 4
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: